SaSPinjara Life Sciences sees Indian pharma boosting capability in high-demand therapeutics: Nandita Vijayasimha, Bengaluru Saturday, February 1, 2025, 08:00 Hrs [IST] SaSPinjara ...

Viehbacher, “Biogen”) announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as treatment for early AD (mild cognitive impairment due to ...

Global Cell-Based Assays Market size is expected to be worth around US$ 37.1 Billion by 2032 from US$ 17.7 Billion in 2023, growing at a CAGR of 8.8% ...

ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung cancer.

PRINCETON, N.J. - Bristol Myers Squibb (NYSE: BMY), a prominent pharmaceutical company with a market capitalization of nearly $120 billion and impressive gross profit margins of 76%, received a ...

Rahul Saluja, Senior Executive and Thought Leader in Life Sciences.

Kentucky hemp farmers are questioning the legitimacy of how some medical cannabis cultivators got picked and the state auditor could be investigating the process.

Human Organs-on-Chips Market is Segmented by Type (Brain-on-a-chip, Liver-on-a-chip, Kidney-on-a-chip, Lung-on-a-chip, Heart-on-a-chip, Intestine-on-a-chip, Vessel-on-a-chip), by Application ...

Bioretec Ltd., a pioneer in absorbable orthopedic implants, has successfully completed its CE mark approval process and can start commercialization of its RemeOs™ Trauma Screw product portfolio within ...

The global Synthetic Lubricants Market is expected to grow at 5.10% CAGR from 2023 to 2030. It is expected to reach above USD 38.9 billion by 2030 from USD 24.2 billion in 2023. List of the Top Key ...

Represents net earnings attributable to AbbVie Inc. Intangible asset impairment reflects a partial after-tax impairment charge of $3.5 billion related to the emraclidine intangible asset acquired as ...

Danaher Corporation (NYSE:DHR) reported its fourth-quarter 2024 earnings, revealing a slight miss in earnings per share (EPS) compared to forecasts but surpassing revenue expectations. The company ...